Wells Fargo’s Pasithea Therapeutics KTTA Stock Holding History

Wells Fargo’s Portfolio KTTA Stock Details KTTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-6	Closed	-$44	–	7205
2024 Q1	$44	Hold	6	–	–	﹤0.01%	6859
2023 Q4	$47	Sell	6 -2	-25%	-$15	﹤0.01%	6943
2023 Q3	$72	Buy	8 +2	+33%	+$22	﹤0.01%	6838
2023 Q2	$58	Hold	6	–	–	﹤0.01%	7019
2023 Q1	$48	Hold	6	–	–	﹤0.01%	7120
2022 Q4	$74	Hold	6	–	–	﹤0.01%	6875
2022 Q3	$0	Buy	6 +1	+20%	+$23	﹤0.01%	7035
2022 Q2	$0	Buy	5 +1	+25%	+$21	﹤0.01%	7176
2022 Q1	$0	Buy	4 +2	+100%	+$51	﹤0.01%	7471
2021 Q4	$0	Buy	+2	New	+$104	﹤0.01%	7547

Other funds holding KTTA

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo's KTTA Position: Q2 2024 in Review

Wells Fargo sold out of Pasithea Therapeutics (KTTA) in Q2 2024, closing a stake of 6 shares — an estimated $44 sold.

Wells Fargo first reported a position in KTTA in Q4 2021 and held it in 10 quarters. The position peaked at $74 in Q4 2022. 7 funds tracked by Wall St. Rank hold KTTA as of Q2 2024.

Wells Fargo reported no remaining Pasithea Therapeutics position as of Q2 2024 after selling out during the quarter.
Wells Fargo sold 6 Pasithea Therapeutics shares in Q2 2024, an estimated $44.
Wells Fargo first reported a position in Pasithea Therapeutics in Q4 2021 and held it in 10 quarters.
Wells Fargo's Pasithea Therapeutics position peaked at $74 in Q4 2022.
7 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q2 2024.

Based on Wells Fargo's 13F filing for Q2 2024, filed 13 Aug 2024.